These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 20455347)

  • 1. Evaluation of treatment risks: taking clinical data, pharmacology and patient characteristics into account.
    Prescrire Int; 2010 Feb; 19(105):44-5. PubMed ID: 20455347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretation of drug risk and benefit: individual and population perspectives.
    Bjornson DC
    Ann Pharmacother; 2004 Apr; 38(4):694-9. PubMed ID: 14990777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology in the geriatric patient.
    Hilmer SN; McLachlan AJ; Le Couteur DG
    Fundam Clin Pharmacol; 2007 Jun; 21(3):217-30. PubMed ID: 17521291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
    Andrews E; Dombeck M
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing therapeutic benefit and risk.
    Meyboom RH; Egberts AC
    Therapie; 1999; 54(1):29-34. PubMed ID: 10216419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drugs during pregnancy and breastfeeding: new risk categories--antibiotics as a model].
    Bertsche T; Haas M; Oberwittler H; Haefeli WE; Walter-Sack I
    Dtsch Med Wochenschr; 2006 May; 131(18):1016-22. PubMed ID: 16673226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process.
    Laenge R; Steger-Hartmann T; Schweinfurth H
    Regul Toxicol Pharmacol; 2006 Aug; 45(3):223-8. PubMed ID: 16716476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose chemotherapy and hematopoietic stem cell transplantation: a study of treatment preference in patients with rheumatoid arthritis and rheumatologists.
    Verburg RJ; Mahabali SD; Stiggelbout AM; Sont JK; van Laar JM
    J Rheumatol; 2002 Aug; 29(8):1653-8. PubMed ID: 12180724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [General principles for safety evaluation of pharmaceuticals in man based on integration of data from various sources].
    Hayashi Y
    Eisei Shikenjo Hokoku; 1993; (111):143-4. PubMed ID: 7920559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.